Evidence verdict: A plausible mechanism helps explain why scientists investigate a therapy. It does not establish that a specific product improves a specific disease in humans.
Mesenchymal stromal cells, often called mesenchymal stem cells or MSCs, are studied in regenerative medicine. The important question for patients is more specific than whether these cells are interesting: what evidence supports the exact treatment being offered?
Signaling is a research rationale
Researchers investigate interactions between MSCs, immune cells and surrounding tissue. In osteoarthritis, many explanations involving secreted factors and tissue repair come from laboratory and animal work. Their contribution to clinical outcomes in human joints remains uncertain. 2026 osteoarthritis cell-therapy review.
For that reason, an illustration of a signaling pathway should be labeled as a mechanism under study. It should not be paired with language promising that a patient’s cartilage, nerves or heart muscle will regenerate.
Do cells travel exactly where they are needed?
Before accepting a claim that an IV infusion targets a damaged organ, ask for human evidence measuring delivery of that particular product by that route. The presence of a biological targeting hypothesis does not establish how many viable cells reach a target, how long they remain, or whether the patient benefits.
We should not assign a universal percentage to how much of MSC therapy works through signaling, nor describe a predictable timetable of integration into new tissue without suitable evidence.
Immune effects can have legitimate clinical value
In December 2024, the FDA approved Ryoncil, a donor bone-marrow-derived MSC product, for steroid-refractory acute graft-versus-host disease in children aged two months and older. That is an important example of clinical progress. It does not validate different cord-derived products or broad wellness claims. FDA approval announcement.
Safety is specific, too
The same approval announcement describes infusion reactions and other potential complications. A description such as young cells or natural therapy does not remove the need for product-specific screening, monitoring and risk disclosure. The safety of one product cannot be assumed for every product marketed under the MSC label.
A practical standard for evaluating the science
- Identify the source, manufacturing process, dose and delivery route.
- Separate laboratory findings from controlled human results.
- Name the population and outcome actually studied.
- Discuss the comparison treatment, uncertainty and adverse events.
- Ask whether the proposed clinic treatment matches the evidence.
Regenerative medicine can be both promising and uncertain. Explaining that distinction accurately is part of building trust.
Disclosure: Dr. Ramon De La Puerta is affiliated with Z-Lounge Regenerative Medicine and has a commercial interest in regenerative-medicine services. This relationship should be considered when reading this article. The discussion is educational and does not determine whether a treatment is appropriate for an individual patient.
Correction — September 11, 2026: This revision removes descriptions of guaranteed organ targeting, automatic tissue replacement, universal immune safety, no tumor risk and an unsupported percentage assigned to paracrine effects.
